Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974686 · ClinicalTrials.gov registry record · Phase 4
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
A Phase 4 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT02974686: Clinical Trial Phase 4 study, sponsored by Washington University School of Medicine.
NCT02974686 is a Phase 4 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02974686, a Phase 4 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
Patients who receive renal transplantation at Barnes Jewish Hospital (BJH) are placed on triple maintenance immunosuppression, which means that patients take 3 types of immunosuppression drugs to suppress their immune system including tacrolimus, mycophenolate (MPA), and prednisone. However, due to the effects of MPA on the gastrointestinal tract, patients often complain of GI adverse effects. Current practice is to either dose-reduce MPA or convert the patient to an alternative agent, typically Azathioprine. Both of these strategies have limitations, largely due to concerns related to efficacy. Everolimus (EVR) has demonstrated similar efficacy to MPA in renal transplantation and may offer a benefit related to GI adverse effects, so the investigators will convert patients to EVR in this study. Patients who are within their first year post-transplant will be converted to EVR upon enrollment in the study, and serial measurements ,or a series of measurements looking for an increase or decrease over time, of GI adverse effects will be conducted over 1 year post-enrollment.
Primary Outcome
Trial was terminated with only 1 participant enrolled. No data is reported here to maintain patient confidentiality.
Interventions
- DRUG Everolimus
- DRUG Mycophenolic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-09 |
| Phase | Phase 4 |
Why NCT02974686 stopped before completion
NCT02974686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT02974686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02974686 about?
NCT02974686 is a clinical study titled "Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation". Patients who receive renal transplantation at Barnes Jewish Hospital (BJH) are placed on triple maintenance immunosuppression, which means that patients take 3 types of immunosuppression drugs to suppress their immune system including tacrolimus, mycophenolate (MPA), and prednisone. However, due to ...
What is the current status of trial NCT02974686?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2016-11. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02974686?
The interventions under investigation include: Everolimus (DRUG), Mycophenolic Acid (DRUG).
Who is sponsoring clinical trial NCT02974686?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02974686's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia